---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-129971"
form_type: "8-K"
ticker: "APVO"
cik: "0001671584"
company_name: "Aptevo Therapeutics Inc."
filed_at: "2024-11-22T23:59:59+00:00"
generated_at: "2026-05-29T19:47:16.823559+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "medium"
source: SEC EDGAR
---

# Aptevo highlights bispecific pipeline; first AML patient shows 90% blast reduction

## Summary
- First patient in Phase 1b/2 RAINIER trial for mipletamig achieved 90% leukemic blast reduction within 30 days.
- ALG.APV-527 Phase 1 data: 9 of 16 evaluable patients (56%) achieved stable disease; safety and tolerability positive.
- Preclinical candidates APVO711, APVO603, APVO442 target PD-L1/CD40, 4-1BB/OX40, PSMA/CD3 respectively.
- Company plans to add another targeted asset to pipeline in near-term but provides no details.
- No financial updates or guidance provided; no leadership or corporate changes.

## SEC filing metadata
- accession: 0000950170-24-129971
- form_type: 8-K
- ticker: APVO
- cik: 0001671584
- company_name: Aptevo Therapeutics Inc.
- filed_at: 2024-11-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671584/000095017024129971/0000950170-24-129971-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671584/000095017024129971/apvo-20241122.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-129971
- JSON: https://secwatch.observer/filing/0000950170-24-129971.json
- Plain text: https://secwatch.observer/filing/0000950170-24-129971.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.